Dendreon Corp fka DNDNQ

[Biowatch]

>The DNDN non-disclosure problem is compounded by the fact that in the 10K issued in March and signed by every Director escept Susan Bayh, they not only fail to list the preapproval inspection and its outcome in the Section describing Ongoing Regulatory Activity, but describe the requirement for the inspection as something that hadn't occurred yet. Both the CEO and the CFO certified the 10K per Sarbanes Oxley as being materially accurate.<

Out of curiosity, so you know why Susan Bayh did not sign it? Was this typical for her or unusual? (Or was she just not there at the time.)

Thanks in advance.

I also thought Gold's stock sale seemed strange, given that the advisory panel vote was better than I expected in regards to efficacy.

I don't know what the manufacturing issues are, but DNDN's approach is more labor intensive than most, and will require meticulous cleanliness, record keeping, and tracking to make sure that each patient receives their own cells back free of contamination.